Zobrazeno 1 - 10
of 52
pro vyhledávání: '"C. Lebedinsky"'
Publikováno v:
HemaSphere, Vol 6, Pp 934-935 (2022)
Externí odkaz:
https://doaj.org/article/0104dbb28d6146ab8e94819472edbc2a
Autor:
R. Joe, Y. Matsumura, A. Siddiqui, J. Foulks, M. Beg, J. Thompson, N. Yamamoto, A. Spira, J. Sarantopoulos, J. Melear, Y. Lou, C. Lebedinsky, J. Li, A. Watanabe, S. Warner
Publikováno v:
European Journal of Cancer. 174:S57-S58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9640d9635f5dee9d144582917e37649
https://doi.org/10.1016/s0959-8049(22)00954-6
https://doi.org/10.1016/s0959-8049(22)00954-6
Autor:
S. Verstovsek, J. Mertz, John Mascarenhas, V. Gupta, G. Schiller, S. Kabir, Robert S. Hoffman, J. Supko, J. Piel, C. Lebedinsky, Patrick Trojer, P. Bose, A. Senderowicz, A. Godfrey, E. Liew, Marina Kremyanskaya
Publikováno v:
HemaSphere. 3:369
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2b68c23842e9ce85c790783ded2de69b
https://doi.org/10.1097/01.hs9.0000561604.66251.2e
https://doi.org/10.1097/01.hs9.0000561604.66251.2e
Autor:
Margarita Majem, Vicente Alfaro, Hernán Cortés-Funes, M.G. Garcia, Eva Ciruelos, C. Lebedinsky, Ramon Salazar, Carmen Cuadra, Arturo Soto-Matos, Luis Paz-Ares, Ana Montes, Beatriz Pardo
Publikováno v:
Medical Oncology. 29:2240-2250
Maximum tolerated dose (MTD), recommended dose (RD), and pharmacokinetics (PK) were evaluated for trabectedin 3-h every-3-weeks schedule in 33 cancer patients stratified according to liver dysfunction degree as per baseline alkaline phosphatase (AP).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c4c2c9f04b24b12957eb870df61dec
https://doi.org/10.1007/s12032-011-9979-8
https://doi.org/10.1007/s12032-011-9979-8
Autor:
Patrick Trojer, Ian W. Flinn, Kami J. Maddocks, Jeremy S. Abramson, C. Lebedinsky, A. Senderowicz, William D. Bradley, Matthew A. Lunning, Andre Goy, W. Harb
Publikováno v:
Annals of Oncology. 29:iii7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96d266b7d131f54f7fa2e7cd8779181f
https://doi.org/10.1093/annonc/mdy048.001
https://doi.org/10.1093/annonc/mdy048.001
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Nicoletta Colombo, Hans Hagberg, Stan B. Kaye, Ignace Vergote, Andres Poveda, Bradley J. Monk, C. Lebedinsky, P. Santabarbara, Youn C. Park, Antonio Nieto, Stephen Chan, E. Filipczyk-Cisarz, Sergei Tjulandin, B. Kong, M. Roy, Trilok V. Parekh
Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD; CentoCor Ortho Biotech Products L.P., Raritan, NJ, USA). over single-agent PLD in 672 patients with relapsed ovarian can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1bc3d93dcf06788d6b347257656bba2
http://hdl.handle.net/10281/17241
http://hdl.handle.net/10281/17241
Autor:
Ana Montes, M.G. Garcia, Margarita Magem, Stan B. Kaye, Clare Barlow, Amalia Florez, Ian Judson, Ramon Salazar, C. Lebedinsky, Laura Vidal, Beatriz Pardo
Publikováno v:
Investigational new drugs. 30(2)
Purpose This study intended to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RD) of trabectedin combined with carboplatin in patients with advanced solid tumors. Patients and methods Carboplatin-pretreated patients rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73da746cb3e175b7bfb5e37a37ff7b32
https://pubmed.ncbi.nlm.nih.gov/20927639
https://pubmed.ncbi.nlm.nih.gov/20927639
Autor:
J M, Del Campo, A, Roszak, M, Bidzinski, T E, Ciuleanu, T, Hogberg, M Z, Wojtukiewicz, A, Poveda, K, Boman, A M, Westermann, C, Lebedinsky, T J, Perren
Publikováno v:
Annals of oncology, 20(11), 1794-1802. Oxford University Press
This randomized, open-label, phase II clinical trial evaluated the optimal regimen of trabectedin administered every 3 weeks in patients with platinum-sensitive, relapsed, advanced ovarian cancer (AOC). Patients previously treated with less than two
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4fa79b67a47307098e930339da9e9e2
https://pubmed.ncbi.nlm.nih.gov/19556318
https://pubmed.ncbi.nlm.nih.gov/19556318